EGFR is a cell-surface receptor tyrosine kinase, and activated by binding of its specific ligand, such as epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha), EGFR overexpression or overactivity have associated with a number of cancers, including the lung cancer and colon cancer. The identification of EGFR as a driver gene has led to the development of anticancer therapeutics agents, including Gefitinib, Erlotinib, Afatinib, Osimertinib (AZD9291) and Cetuximab.
|Immunogen:||A phospho-peptide corresponding to human Phospho- EGFR (Tyr1173)|
|Synonyms:||Epidermal growth factor receptor, ERBB, ERBB1, HER1|
|Observed MW:||Refer to figure|
|Specificity:||This antibody reacts to human EGF Receptor only when phosphorylated at Tyr1173. There is no cross-reactivity to EGFR without phosphorylation at Tyr1173.|
IHC: 1:1000 – 1:5000
WB: 1:500 -1:1000
|Purification Method:||Protein A affinity purified from an animal origin–free culture supernatant|
|Buffer:||50% Glycerol/PBS with 1% BSA and 0.09% sodium azide|
|Storage Conditions:||Stable for 1 year at -20.0°C from date of receipt.|
FOR RESEARCH USE ONLY. NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE.